MX339762B - Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. - Google Patents

Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.

Info

Publication number
MX339762B
MX339762B MX2011010190A MX2011010190A MX339762B MX 339762 B MX339762 B MX 339762B MX 2011010190 A MX2011010190 A MX 2011010190A MX 2011010190 A MX2011010190 A MX 2011010190A MX 339762 B MX339762 B MX 339762B
Authority
MX
Mexico
Prior art keywords
agent
individuals
immunomodulator
metallopeptide
humans
Prior art date
Application number
MX2011010190A
Other languages
English (en)
Other versions
MX2011010190A (es
Inventor
Jorge Alberto Reyes-Esparza
María De Lourdes Rodríguez-Fragoso
Ana Laura Badillo-Jiménez
Lorena Julieta Torres-Aguilar
Martínez Lorenzo Ulises Osuna
De Los Ríos-Corsino Abril Arianna Martínez
Carlos Antonio Arjona-Canul
Hugo Morales-Rojas
Original Assignee
Univ Autonoma Del Estado De Morelos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Autonoma Del Estado De Morelos filed Critical Univ Autonoma Del Estado De Morelos
Priority to MX2011010190A priority Critical patent/MX339762B/es
Priority to EP11872934.2A priority patent/EP2805962A4/en
Priority to CN201180075048.3A priority patent/CN103974968A/zh
Priority to US14/348,326 priority patent/US20150132328A1/en
Priority to PCT/MX2011/000117 priority patent/WO2013048226A1/es
Publication of MX2011010190A publication Critical patent/MX2011010190A/es
Publication of MX339762B publication Critical patent/MX339762B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C07K7/065—Thymic humoral factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un metalopéptido inmunomodulador, caracterizado porque comprende: a) Un péptido de fórmula : Xn-Asp-Gly-Pro-Lus-Phe-Leu-Xm donde Xn y Xm son cualquier aminoácido independientemente uno del otro, n tiene un valor de 0 a 4, m tiene un valor de 0 a 2, y b) Un ión divalente seleccionado del grupo que comprende Zn2+, Cu2+, Mg2+ o mezclas de los mismos, donde el péptido el ión divalente se encuentran unidos entre sí por un enlace no covalente.
MX2011010190A 2011-09-28 2011-09-28 Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. MX339762B (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2011010190A MX339762B (es) 2011-09-28 2011-09-28 Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
EP11872934.2A EP2805962A4 (en) 2011-09-28 2011-10-04 IMMUNOMODULATORY METALLOPEPTIDES (IMMP) AND COMPOSITIONS CONTAINING THE SAME
CN201180075048.3A CN103974968A (zh) 2011-09-28 2011-10-04 免疫调节剂金属肽(immp)和包含其的组合物
US14/348,326 US20150132328A1 (en) 2011-09-28 2011-10-04 Immunomodulator metallopeptides (immps) and compositions containing same
PCT/MX2011/000117 WO2013048226A1 (es) 2011-09-28 2011-10-04 Metalopéptidos inmunomoduladores (immp) y composiciones que los contienen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011010190A MX339762B (es) 2011-09-28 2011-09-28 Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.

Publications (2)

Publication Number Publication Date
MX2011010190A MX2011010190A (es) 2013-03-28
MX339762B true MX339762B (es) 2016-05-27

Family

ID=47996048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010190A MX339762B (es) 2011-09-28 2011-09-28 Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.

Country Status (5)

Country Link
US (1) US20150132328A1 (es)
EP (1) EP2805962A4 (es)
CN (1) CN103974968A (es)
MX (1) MX339762B (es)
WO (1) WO2013048226A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705768D0 (en) * 2017-04-10 2017-05-24 Kanu Ifeyinwa Rita Anaerobic digester
CU24626B1 (es) 2019-12-26 2022-11-07 Centro Nac De Biopreparados Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7502830A (nl) 1974-03-25 1975-09-29 Jean Francois Bach En Dr Jean Werkwijze voor het isoleren van een polypeptide hormoon.
US4098777A (en) 1977-03-14 1978-07-04 Merck & Co., Inc. Process for the preparation of pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn
US4621135A (en) 1983-12-08 1986-11-04 Yeda Research & Development Company, Ltd. Novel THF compositions
IL85207A (en) 1987-02-06 1992-06-21 Daiichi Seiyaku Co 6-substituted thiazolo-(and 1,3,4-thiadiazolo-)(3,2-a)-(1,2,3)triazolo(4,5-d)pyrimidin-9(1h)-ones and their preparation
GB8723485D0 (en) * 1987-10-07 1987-11-11 Erba Farmitalia Solution synthesis of octapeptide
IL106214A (en) * 1993-07-01 1998-12-06 Yeda Res & Dev Thf-gamma2 analogs and pharmaceutical compositions comprising them
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
US20070031372A1 (en) 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
IL160882A0 (en) 2001-09-28 2004-08-31 Intermune Inc Method for treating hepatitis c virus infection in treatment failure patients
AU2002357283B2 (en) 2001-12-17 2007-08-16 Zymogenetics, Inc. Method for treating cervical cancer
EP1546186A4 (en) * 2002-08-26 2006-02-08 A & Pep Inc PROCESS FOR SYNTHESIS OF PEPTIDES
US20070134242A1 (en) 2003-10-17 2007-06-14 Chugai Seiyaku Kabushiki Kaisha Mesothelioma therapeutic agent
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
RU2007142523A (ru) 2005-05-18 2009-06-27 БИОГЕН ИДЕК Инк. (US) Способы лечения фиброзных состояний
EP2029608A1 (en) 2006-06-06 2009-03-04 Boehringer Ingelheim International GmbH Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
US20100015724A1 (en) * 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
EP2712930A3 (en) 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
US20080269065A1 (en) * 2007-04-30 2008-10-30 Syntrix Biosystems, Inc. Conformationally Constrained Analytical Probes
EP2150258A2 (en) 2007-06-01 2010-02-10 Innate Pharma S.A. Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
WO2009114869A2 (en) 2008-03-14 2009-09-17 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
DE102008044911B3 (de) 2008-08-29 2009-12-03 Universität Leipzig Verfahren und Mittel zur Aktivierung von Gedächtnis-B-Lymphozyten
IN2012DN00446A (es) 2009-07-30 2015-05-15 Pfizer Vaccines Llc

Also Published As

Publication number Publication date
MX2011010190A (es) 2013-03-28
EP2805962A4 (en) 2015-05-06
WO2013048226A1 (es) 2013-04-04
US20150132328A1 (en) 2015-05-14
CN103974968A (zh) 2014-08-06
EP2805962A1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
MD20140134A2 (ro) Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
PH12014501045B1 (en) Purine derivatives for the treatment of viral infections
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
CA2871471C (en) Dna-pk inhibitors
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
IN2014CN03113A (es)
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2013003635A (es) Compuestos de n-heteroarilo.
EA201490254A1 (ru) Комбинированное лечение гепатита с
ZA202002093B (en) Antibacterial compounds
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
EA201691330A1 (ru) Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
PH12020551994A1 (en) Tlr7 agonists

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration